Recce Pharmaceuticals receives ethics approval to start Phase I/II study evaluating topical spray-on synthetic antibiotic RECCEÂ® 327 on chronic burn wounds
Recce Pharma Ltd, the Company developing new classes of synthetic anti-infectives, announced it has received Human Research Ethics Committee approval to start a Phase I/II clinical trial of its broad-spectrum antibiotic RECCE® 327 on patients with infected burn wounds. The clinical study is anticipated to be sponsored by the South Metropolitan Health Service, Department of Health, Government of Western Australia. The Fiona Stanley Hospital has been nominated as the study site and a separate trial agreement will be finalized in due course.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063